Bimagrumab: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข4 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: As a monoclonal antibody, bimagrumab requires refrigerated storage (2-8 degrees C) and protection from light. It must not be frozen. Storage and handling are managed by clinical trial sites per sponsor protocols. The drug is not available for self-administration or home storage.
Protocol Quick-Reference
Body composition improvement (fat loss with muscle preservation)
Dosing
Amount
10 mg/kg
Frequency
Every 4 weeks (Q4W)
Duration
48 weeks
Administration
Route
IVTiming
Administered as IV infusion at clinical sites. The BELIEVE trial used approximately Q12W dosing (4 infusions over 48 weeks) in combination with semaglutide.
Cycle
Duration
48 weeks
Repeatable
Yes
โ๏ธ Suggested Bloodwork (4 tests)
DEXA body composition scan
When: Baseline
Why: Baseline fat mass and lean mass measurement
HbA1c
When: Baseline
Why: Baseline glycemic control assessment
CMP (Comprehensive Metabolic Panel)
When: Baseline
Why: Baseline liver and kidney function
DEXA body composition scan
When: 24 weeks
Why: Monitor fat mass and lean mass changes
๐ก Key Considerations
- โInvestigational drug: not approved by any regulatory agency
- โMonoclonal antibody requiring IV infusion: not available for self-administration
- โCommon side effects include muscle spasms, diarrhea, and acne
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Obesity and Body Composition (Phase 2, T2D) | 10 mg/kg IV every 4 weeks for 48 weeks. In the Heymsfield et al. (JAMA Network Open 2021) trial, this dose produced 20.5% fat mass loss and 3.6% lean mass gain in adults with T2D and obesity (BMI 28-40). | Every 4 weeks (Q4W) intravenous infusion | 48 weeks in the Phase 2 RCT | Both groups received diet and exercise counseling. This is the only dose tested in the obesity RCT. Optimal dose for body composition effects not fully established. |
| BELIEVE Combination Trial (Obesity, with Semaglutide) | Bimagrumab IV infusion at weeks 4, 16, 28, and 40 in combination with semaglutide SC weekly. The combination achieved 22.1% total weight loss with 92.8% from fat mass and preserved 67% more lean mass than semaglutide alone. | IV infusion approximately every 12 weeks (4 total infusions) | 48 weeks | Phase 2b trial with 507 participants. Semaglutide was administered as standard weekly subcutaneous injection. Specific bimagrumab dose (mg/kg) from BELIEVE should be confirmed from primary publication. |
| Sarcopenia (Phase 2 Proof-of-Concept) | 30 mg/kg IV in community-dwelling older adults (65+) with sarcopenia. Increased muscle mass and strength over 16 weeks. | Single dose or repeated IV infusions | 16 weeks in the proof-of-concept study | Higher dose (30 mg/kg) used in sarcopenia vs obesity (10 mg/kg). Small proof-of-concept (n=40). Dose-response relationship across indications not fully characterized. |
| Inclusion Body Myositis (RESILIENT Phase 2b/3) | 1, 3, or 10 mg/kg IV every 4 weeks for 52 weeks. The primary endpoint (6-minute walk distance) was not met at any dose. Dose-response analysis showed no clear dose-response relationship for functional outcomes. | Every 4 weeks (Q4W) intravenous infusion | 52 weeks (core study) | Largest IBM trial (n=251) at 38 sites. Failed primary endpoint at all dose levels. 10 mg/kg showed some patient-reported outcome preservation. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
Bimagrumab is supplied as a sterile solution for IV infusion in clinical trial settings. It is not available as a lyophilized powder for reconstitution by end users. All preparation and administration occurs within clinical trial sites under medical supervision.
๐งStorage Requirements
As a monoclonal antibody, bimagrumab requires refrigerated storage (2-8 degrees C) and protection from light. It must not be frozen. Storage and handling are managed by clinical trial sites per sponsor protocols. The drug is not available for self-administration or home storage.
Community Dosing Protocols
Compare these clinical doses with what 40+ community members report using.
Based on 40+ community reports
View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Investigational Drug Status#
Bimagrumab is an investigational drug available only within clinical trials. It is not approved by any regulatory agency and cannot be obtained through prescription, pharmacy, or research peptide suppliers. All dosing information below is from published clinical trials.
Administration Route#
Bimagrumab is administered as an intravenous (IV) infusion, not as a subcutaneous injection. This distinguishes it from most peptides and many modern biologics that allow self-injection. IV infusion requires:
- Clinical site with infusion capability
- Healthcare professional supervision during administration
- Infusion duration typically 30-60 minutes
- Post-infusion monitoring period
Clinical Trial Dosing#
Obesity/T2D (JAMA Network Open 2021)#
| Parameter | Value |
|---|---|
| Dose | 10 mg/kg body weight |
| Route | Intravenous infusion |
| Frequency | Every 4 weeks (Q4W) |
| Duration | 48 weeks (12 infusions) |
| Population | Adults with T2D and BMI 28-40 |
| Key outcome | 20.5% fat loss, 3.6% lean mass gain |
BELIEVE Trial (Obesity Combination)#
| Parameter | Value |
|---|---|
| Bimagrumab | IV infusion at weeks 4, 16, 28, 40 |
| Semaglutide | SC weekly (standard dosing) |
| Duration | 48 weeks |
| Population | Adults with overweight or obesity |
| Key outcome | 22.1% weight loss, 67% more lean mass preserved |
IBM (RESILIENT, Lancet Neurology 2019)#
| Parameter | Value |
|---|---|
| Doses tested | 1, 3, and 10 mg/kg |
| Route | Intravenous infusion |
| Frequency | Every 4 weeks (Q4W) |
| Duration | 52 weeks (core), plus extension |
| Primary endpoint | 6-minute walk distance (NOT MET) |
Sarcopenia (JAGS 2017)#
| Parameter | Value |
|---|---|
| Dose | 30 mg/kg body weight |
| Route | Intravenous infusion |
| Duration | 16 weeks |
| Population | Adults 65+ with gait speed 0.4-1.0 m/s |
Dose Comparison Across Indications#
| Indication | Dose | Frequency | Result |
|---|---|---|---|
| Obesity/T2D | 10 mg/kg | Q4W | Positive (fat loss + lean gain) |
| Obesity combo | Variable | ~Q12W | Positive (BELIEVE) |
| Sarcopenia | 30 mg/kg | Variable | Positive (proof-of-concept) |
| IBM | 1-10 mg/kg | Q4W | Negative (primary endpoint) |
The higher dose used in sarcopenia (30 mg/kg) vs obesity (10 mg/kg) may reflect different therapeutic requirements for muscle anabolism in aged, sarcopenic populations.
Not Available for Self-Administration#
Key points about bimagrumab availability:
- Not a peptide: Cannot be synthesized by peptide suppliers
- Monoclonal antibody: Requires mammalian cell production and GMP manufacturing
- IV only: Cannot be self-injected subcutaneously
- Clinical trial only: No approved formulation exists
- No generic or biosimilar: Patent-protected investigational agent
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Bimagrumab
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.